Navigation Links
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Date:5/8/2008

- Memorial Sloan-Kettering Cancer Center Investigators to Assess BSI-201

Therapy in BRCA-Negative Ovarian Cancer Patients -

BRISBANE, Calif., May 8 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on-going trials in breast and brain cancer.

The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. Clinicians at Memorial Sloan-Kettering Cancer Center will enroll patients who have a mutation in their BRCA1 or BRCA2 genes.

"We believe BSI-201 holds great promise as a targeted therapy in this difficult-to-treat type of ovarian cancer," said Carol Aghajanian, M.D., co- principal investigator and chief of the gynecologic medical oncology service at Memorial Sloan-Kettering Cancer Center. "BRCA-negative patients are at higher risk of breast and ovarian cancer because BRCA plays a key role in repairing DNA errors that lead to tumor formation."

Ovarian cancer strikes more than 21,000 women a year in the United States and is one of the most common causes of cancer death in women, killing more than 15,000 annually in the United States. Patients with the hereditable BRCA- negative form of the disease account for about 15 percent of the patient population. Women with defective BRCA genes are also at considerably higher risk of breast cancer.

"We have identified a number of important types of cancer where PARP plays a crucial role in tumor growth, and we believe that BRCA-negative ovarian cancer represents another excellent target for BSI-201," said Barry Sherman, M.D., BiPar's Executive Vice President of Development. "We will soon have patients enrolled in four separ
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
7. Neurocrine Biosciences Reports First Quarter 2008 Results
8. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
9. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009).... 25 NuVasive, Inc. (Nas...developing products for minimally disruptive surgi... it will host a conference call on Monday, Novembe...onference call will focus on current issues relati... will include comments from management followed by...
(Date:11/25/2009)...5 Reportlinker.com announces that ...atalogue: ,, Intranasal Drug Delivery - US Mar...r.com/p0164267/Intranasal-Drug-Delivery---US-Marke...rug delivery market is witnessing an expansion of ...entional local therapeutic drugs to the delivery o...
(Date:11/25/2009)...Nov. 25 ChemoCentryx, Inc., anno...he Company,s PROTECT-1 (the Prospective Randomized... of Traficet-EN(TM) (CCX282-B) in patients with mo...ical efficacy with a favorable safety and tolerabi...clinical efficacy in the reduction of disease seve...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 1President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 2President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 3Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 1Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 2Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 3Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 4Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 5Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 6Digirad Corporation Reports Second Quarter 2009 Financial Results 52497 7St John 26apos 3Bs Hospital Acquires Latest Technology in Robotic Assisted Surgery 52495 1St John 26apos 3Bs Hospital Acquires Latest Technology in Robotic Assisted Surgery 52495 2St John 26apos 3Bs Hospital Acquires Latest Technology in Robotic Assisted Surgery 52495 3
...., April 15 Pharmacopeia,(Nasdaq: PCOP ), an inn...mall molecule therapeutics, announced today that r...evaluating PS433540, its first-in-class,Dual Actin... a,late-breaking clinical trial at the American So...ientific Meeting and Exposition in New Orleans, Ma...
...15 It is commonly known that many,children get fa...ut as a,person ages, their skin is supposed to cle...of adults who still suffer,from these kinds of fac...with FaceDoctor] says:, "In the western hemispher...but as a bacterial infection.", "If a person with...
Other Medicine Technology:Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540 2Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540 3Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540 4Clinically Proven Treatment Offers Help to Rosacea Sufferers 2
(Date:11/27/2009)...l, Nov. 27 Shamir Optica...eading provider of innovative products and technol... that its board of directors had declared a divide...illion (approximately NIS 37.62 million based on t...ge), or approximately US$ 0.609 (approximately NIS...
(Date:11/27/2009)...e/-- Allrecipes.com , theworld,s#1foodsite,receiv...an2.8millionvisitorsthedaybeforeThanksgiving,provi...lidayoftheyear.TheaverageThanksgivingmealin2009wei...romlastyear,sfeast.AccordingtotheAllrecipessite, S...ivingrecipe,acontrastfromlastyear,spopular Homesty...
(Date:11/27/2009)...new interactive anatomy education apps from Modali...alth sciences learning opportunities for iPhone an... (Vocus) November 27, 2009 -- Modality, Inc. and...on of Wolters Kluwer Health, today announced the a... the App Store. Clemente’s Anatomy, Rohen&rs...
(Date:11/26/2009)...etrathiomolybdate (TM) has been shown in studies t... a disease caused by an overload of copper, and ce... little, however, is known about how the drug work...orthwestern University researchers now has provide...ure of TM bound to copper-loaded metallochaperones...
(Date:11/26/2009)...vid Kim of the Live Life Again Center, a practice ...f a growing number of physicians who are taking a...nect with individuals who are interested in surgic...Dr. Kim is utilizing Facebook to share before-and-...th the community. , Dalla...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3
... 24 SpectraScience, Inc. (OTC,Bulletin Board: SCI...y,announced that it has established a distribution...a Company, a Prague-based firm specializing in,med...public is attractive on many fronts as an entry,po...
...rom the American Cancer Society finds black and Hi...ive and use smoking cessation advice and aids. The... Journal of Preventive Medicine, also finds men an...l and ethnic minority populations bear a dispropor...
...oundation Continues Commitment to ,Keeping the ,Ca...NGLEWOOD CLIFFS, N.J., April 24 As the 2008,natio...ins a voter hot,button and a constant debate issue...health care. But what defines ,quality,health care...
...e is available in Spanish . , The risk of suffe...rison with non-smokers. This was the conclusion of...entists of the University of Navarra, in collabora...irect relationship between tobacco use and this di...
...her and Translation Specialist Barbara Gandek Join..., LINCOLN, R.I., April 24 As part of its continu...etric today announced that,Barbara Gandek, MS has ...ation & Research Officer and continue to,work clos...
...ciation for International Cancer Research this wee...ject led by Dr Joe Tiralongo to further develop a ...mising results in lab tests. , The grant will en...Glycomics, Queensland said the compounds target a ...
Other Medicine News:Health News:SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic 2Health News:Study finds racial disparities in smoking cessation treatment 2Health News:New National Survey Reveals 8 out of 10 Americans Claim Their Doc Needs a Prescription for Better Bedside Manners 2Health News:New National Survey Reveals 8 out of 10 Americans Claim Their Doc Needs a Prescription for Better Bedside Manners 3Health News:Gandek Joins QualityMetric to Lead International Research Effort 2Health News:$450,000 sweetener in colon cancer battle 2
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
Medicine Products: